



Ref: FLL/COR/09-2

Date: September 09, 2024

The General Manager,
Pakistan Stock Exchange Limited,
Stock Exchange Building,
Stock Exchange Road,
Karachi.

MATERIAL INFORMATION

Dear Sir,

In accordance with Sections 96 and 131 of the Securities Act, 2015 and Clause 5.6.1(a) of the PSX Rule Book, we hereby convey the following information:

1. Brownfield Expansion (Line II) Approval by Drug Regulatory Authority of Pakistan:

We are pleased to inform that BF Biosciences Limited, a subsidiary of Ferozsons Laboratories Limited, has secured approval from the Drug Regulatory Authority of Pakistan (DRAP) for its brownfield expansion (Line II) which includes:

- i. Pre-filled syringes line;
- ii. Liquid and lyophilized line; and
- iii. Product development section.

The commercial production from pre-filled syringes line has commenced, whereas the liquid & lyophilized line is under internal validation and will start commercial production from the second quarter of FY 2024-25.

2. Launch of Sematide (Semaglutide):

BF Biosciences Limited has launched Sematide (Semaglutide) in pre-filled syringe. Sematide is the first Glucagon-Like Peptide 1 (GLP1) receptor agonist approved for local manufacture in Pakistan, offering a convenient solution for diabetes management. The pre-filled syringe eliminates dosing errors and is easy to use by the patients. Sematide is being manufactured at the new state-of-the-art European prefilled syringes line of BF Biosciences Limited.



Raiwind (55150), Pakistan Tel: (+92 42) 3602 6700 Fax: (+92 42) 3602 6701-02 Registered Office:
197 - A, The Mall, Rawalpindi
(46000), Pakistan

Tel: (+92 51) 4252 155-57 Fax: (+92 51) 4252 153 Pharma Factory:
P. O. Ferozsons, Nowshera
(24160), KPK, Pakistan
Tel: (+92 923) 560141

Fel: (+92 923) 560141 (+92 923) 560145 (+92 923) 560148

(+92 923) 560056

Lahore Sales Office: 43 - Al Noor Building, Bank Square, The Mall, Lahore (54000), Pakistan

Tel: (+92 42) 3735 8194 Fax: (+92 42) 3731 3680 Karachi Sales Office:

House No. 9, Maqbool Cooperative Housing Society, Shahrah-e-Faisal Karachi (75350), Pakistan Tel: (+92.21) 3438.6852

Tel: (+92 21) 3438 6852 Fax: (+92 21) 3438 6754





Pakistan has the highest prevalence of diabetes in the world. Even more alarmingly, 8.9 million individuals living with diabetes remain undiagnosed, and half of those who do know are struggling to manage it effectively. With a staggering 29% mortality rate, the need for effective treatment options have never been more urgent.

Following the launch of Ferulin (Human Insulin), the launch of Sematide (Semaglutide) at an affordable price, marks a significant step in our commitment to STOP DIABETES.

Being the 1st Biotech Plant in Pakistan, BF Biosciences Limited has been committed to the production of essential medicines for the treatment of HCV, Cancer, Cardiology and other therapeutic areas for over a decade. We are confident that Ferulin and Sematide will have a positive impact on our subsidiary's growth and will further strengthen our mission to address unmet patient needs.

3. Approval of Listing Application:

We are also pleased to inform that the Securities and Exchange Commission of Pakistan (SECP) and Pakistan Stock Exchange (PSX) has approved the listing application of BF Biosciences Limited.

You are requested to please disseminate the above information to TREC Holders of the Exchange accordingly.

Yours truly,

Syed Ghausuddin Saif
Company Secretary

CC: Director Enforcement - Securities and Exchange Commission of Pakistan.



Tel: (+92 42) 3602 6700 Fax: (+92 42) 3602 6701-02 197 - A, The Mall, Rawalpindi (46000), Pakistan Tel: (+92 51) 4252 155-57 Fax: (+92 51) 4252 153

Tel: (+92 923) 560141 (+92 923) 560145 (+92 923) 560148 (+92 923) 560056 Lahore Sales Office: 43 - Al Noor Building, Bank Square, The Mall, Lahore (54000), Pakistan

Tel: (+92 42) 3735 8194 Fax: (+92 42) 3731 3680 House No. 9, Maqbool Cooperative Housing Society, Shahrah-e-Faisal Karachi (75350), Pakistan

Tel: (+92 21) 3438 6852 Fax: (+92 21) 3438 6754